Download PDF
Exp Clin Endocrinol Diabetes 2021; 129(01): 29-35
DOI: 10.1055/a-0684-9601
Article

The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients

David Slezák
1   Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
,
Otto Mayer
1   Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
,
Jan Bruthans
2   Fakultni Thomayerova nemocnice s poliklinikou, Centre for Cardiovascular Prevention , Praha, Czech Republic
,
Jitka Seidlerová
1   Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
,
Martina Rychecká
3   Fakultni Nemocnice Plzen, Dept. of Cardiology, Plzen, Czech Republic
,
Julius Gelžinský
1   Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
,
Markéta Mateřánková
1   Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
,
Petra Karnosová
1   Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
,
Peter Wohlfahrt
2   Fakultni Thomayerova nemocnice s poliklinikou, Centre for Cardiovascular Prevention , Praha, Czech Republic
,
Renata Cífková
2   Fakultni Thomayerova nemocnice s poliklinikou, Centre for Cardiovascular Prevention , Praha, Czech Republic
,
Jan Filipovský
1   Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
› Author Affiliations Funding: The project was supported by the Health Development Agency of the Czech Ministry of Health [project 17-29520 A], Specific Academic Research Project of Charles University [project SVV 260 393] and Charles University Research Fund [PROGRES, project Q39].
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objectives Impaired glucose metabolism represents one the most important cardiovascular risk factors, with steeply raising prevalence in overall population. We aimed to compare mortality risk of impaired fasting glycaemia (IFG) and overt diabetes mellitus (DM) in patients with coronary heart disease (CHD).

Study design prospective cohort study

Methods A total of 1685 patients, 6–24 months after myocardial infarction and/or coronary revascularization at baseline, were followed in a prospective cohort study. Overt DM was defined as fasting glucose ≥ 7 mmol/L and/or use of antidiabetic treatment, while IFG as fasting glucose 5.6–6.99 mmol/L, but no antidiabetic medication. The main outcomes were total and cardiovascular mortality during 5 years of follow-up.

Results During follow-up of 1826 days, 172 patients (10.2%) deceased, and of them 122 (7.2%) from a cardiovascular cause. Both exposures, overt DM (n=623, 37.0% of the whole sample) and IFG (n=436, 25.9%) were associated with an independent increase of 5-year total mortality, compared to normoglycemic subjects [fully adjusted hazard risk ratio (HRR) 1.63 (95%CI: 1.01–2.61)]; p=0.043 and 2.25 (95%CI: 1.45–3.50); p<0.0001, respectively]. In contrast, comparing both glucose disorders one with each other, no significant differences were found for total mortality [HRR 0.82 (0.53–1.28); p=0.33]. Taking 5-years cardiovascular mortality as outcome, similar pattern was observed [HRR 1.96 (95%CI: 1.06–3.63) and 3.84 (95%CI: 2.19–6.73) for overt DM and IFG, respectively, with HRR 0.63 (95%CI: 0.37–1.07) for comparison of both disorders].

Conclusions Impaired fasting glycaemia adversely increases mortality of CHD patients in the same extent as overt DM.

Keywords

pre-diabetes - secondary prevention - total mortality - fatal vascular events - EUROASPIRE


Publication History

Received: 02 May 2018
Received: 28 July 2018

Accepted: 13 August 2018

Article published online:
29 August 2018

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Di Angelantonio E, Kaptoge S, Wormser D. et al. Association of Cardiometabolic Multimorbidity With Mortality. Jama 2015; 314: 52-60. DOI: 10.1001/jama.2015.7008.
    CrossrefPubMedGoogle Scholar
  • 2 Coutinho M, Gerstein HC, Wang Y. et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240
    CrossrefPubMedGoogle Scholar
  • 3 Chia DB, Wong LY, Liu DYK. et al. Predictive factors of developing type 2 diabetes mellitus, Acute myocardial infarction and stroke in a cohort with Impaired fasting glucose in Singapore. Diabetes Res Clin Pract 2017; 132: 59-67. DOI: 10.1016/j.diabres.2017.07.018.
    CrossrefPubMedGoogle Scholar
  • 4 Xu T, Liu W, Cai X. et al. Risk of coronary heart disease in different criterion of impaired fasting glucose: A meta-analysis. Medicine (Baltimore) 2015; 94: e1740. DOI: 10.1097/md.0000000000001740.
    CrossrefPubMedGoogle Scholar
  • 5 Huang Y, Cai X, Mai W. et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. Bmj 2016; 355: i5953. DOI: 10.1136/bmj.i5953.
    CrossrefPubMedGoogle Scholar
  • 6 Mayer Jr. O, Bruthans J, Seidlerova J. et al. Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients. Eur J Intern Med 2018; 47: 55-61. DOI: 10.1016/j.ejim.2017.07.018.
    CrossrefPubMedGoogle Scholar
  • 7 Angeloni E, Melina G, Benedetto U. et al. Metabolic syndrome affects midterm outcome after coronary artery bypass grafting. Ann Thorac Surg 2012; 93: 537-544. DOI: 10.1016/j.athoracsur.2011.10.066.
    CrossrefPubMedGoogle Scholar
  • 8 Anderson JL, Horne BD, Jones HU. et al. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?. Cardiology 2004; 101: 185-193. DOI: 10.1159/000076695.
    CrossrefPubMedGoogle Scholar
  • 9 Patsa C, Toutouzas K, Tsiamis E. et al. Impact of metabolic syndrome on clinical outcomes after new generation drug-eluting stent implantation: the 'obesity paradox' phenomenon is still apparent. Nutr Metab Cardiovasc Dis 2013; 23: 307-313. DOI: 10.1016/j.numecd.2011.05.002.
    CrossrefPubMedGoogle Scholar
  • 10 Shahim B, De Bacquer D, De Backer G. et al. The prognostic value of fasting plasma glucose, two-hour postload glucose, and hba1c in patients with coronary artery disease: A report from EUROASPIRE IV: A survey from the European Society of Cardiology. Diabetes Care 2017; 40: 1233-1240. DOI: 10.2337/dc17-0245.
    CrossrefPubMedGoogle Scholar
  • 11 Piepoli MF, Hoes AW, Agewall S. et al. 2016; European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. J Prev Cardiol 2016 23: Np1-np96. DOI: 10.1177/2047487316653709.
    CrossrefPubMedGoogle Scholar
  • 12 [Anonymous]. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569-1582
    CrossrefPubMedGoogle Scholar
  • 13 [Anonymous]. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572. 10.1053/euhj.2001.2610
    CrossrefPubMedGoogle Scholar
  • 14 Kotseva K, Wood D, De Backer G. et al. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121-137. DOI: 10.1097/HJR.0b013e3283294b1d.
    CrossrefPubMedGoogle Scholar
  • 15 Kotseva K, Wood D, De Bacquer D et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2015. doi:10.1177/2047487315569401
  • 16 Perk J, De Backer G, Gohlke H. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701. DOI: 10.1093/eurheartj/ehs092.
    CrossrefPubMedGoogle Scholar
  • 17 Mayer OJ, Bruthans J, Timoracká K. The changes in cardiovascular prevention practice between 1995 and 2012 in the Czech Republic. A comparison of EUROASPIRE I, II, III and IV study. Cor Vasa 2013; e91-e97. 10.1016/j.crvasa.2014.01.008
    PubMedGoogle Scholar
  • 18 Warren B, Pankow JS, Matsushita K. et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol 2017; 5: 34-42. DOI: 10.1016/s2213-8587(16)30321-7.
    CrossrefPubMedGoogle Scholar
  • 19 American Diabetes Association Sec. 4. Prevention or Delay of Type 2 Diabetes. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016; 39 (Suppl. 01) S36-S38. 10.2337/dc16-S007
    CrossrefPubMedGoogle Scholar
  • 20 Knowler WC, Fowler SE, Hamman RF. et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686. DOI: 10.1016/s0140-6736(09)61457-4.
    CrossrefPubMedGoogle Scholar
  • 21 Lindstrom J, Ilanne-Parikka P, Peltonen M. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-1679. DOI: 10.1016/s0140-6736(06)69701-8.
    CrossrefPubMedGoogle Scholar
  • 22 Currie CJ, Poole CD, Evans M. et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013; 98: 668-677. DOI: 10.1210/jc.2012-3042.
    CrossrefPubMedGoogle Scholar
  • 23 Colayco DC, Niu F, McCombs JS. et al. A1C and cardiovascular outcomes in type 2 diabetes: A nested case-control study. Diabetes Care 2011; 34: 77-83. DOI: 10.2337/dc10-1318.
    CrossrefPubMedGoogle Scholar
  • 24 Currie CJ, Peters JR, Tynan A. et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489. DOI: 10.1016/s0140-6736(09)61969-3.
    CrossrefPubMedGoogle Scholar
  • 25 Patil HR, Al Badarin FJ, Al Shami HA. et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012; 110: 826-833. DOI: 10.1016/j.amjcard.2012.04.061.
    CrossrefPubMedGoogle Scholar
  • 26 Lamanna C, Monami M, Marchionni N. et al. Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011; 13: 221-228. DOI: 10.1111/j.1463-1326.2010.01349.x.
    CrossrefPubMedGoogle Scholar
  • 27 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128. DOI: 10.1056/NEJMoa1504720.
    CrossrefPubMedGoogle Scholar
  • 28 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322. DOI: 10.1056/NEJMoa1603827.
    CrossrefPubMedGoogle Scholar
  • 29 Chiasson JL, Josse RG, Gomis R. et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Jama 2003; 290: 486-494. DOI: 10.1001/jama.290.4.486.
    CrossrefPubMedGoogle Scholar